Fig. 3

Exo MSC-NTF mitigates pathological lung effects due to LPS administration. a Lung histological sections of (1) healthy controls (no LPS), (2) LPS exposed treated with vehicle (PlasmaLyte), and LPS exposed treated with (3) Exo MSC or (4) Exo MSC-NTF. Quantification of lung damage according to American Thoracic Society documents: b severity score, c alveolar wall thickness, and d fibrin accumulation. e Neutrophil count in lung tissue. Mean ± SEM, n = 9–13. Twenty fields per animal were examined (b-d). ^ap < 0.05 vs. no LPS control; ^bp < 0.05 vs. LPS + PlasmaLyte; ^cp ≤ 0.01 vs. LPS + PlasmaLyte. Kruskal–Wallis followed by Dunn’s post hoc (4b-d) and one-way ANOVA followed by Tukey’s post hoc (e)